- A meta-analysis finds that a shorter course of trastuzumab (
Why this matters
- Findings suggest that 1 year of trastuzumab should remain the standard of care, along with cardiac monitoring.
- Meta-analysis of 6 randomized controlled trials (n=11,603) after search of PubMed and conference abstracts.
- Funding: None.
- Compared with a 1-year course, a shorter trastuzumab course (usually 6 months) is associated with worse DFS (HR, 1.14; P=.003) and worse OS (HR, 1.15; P=.02).
- In subgroup analysis, the worsening of DFS was unaffected by estrogen receptor status (P=.23), nodal involvement (P=.44), or 9- to 12-week duration of trastuzumab in the experimental group (P=.09).
- Compared with a 1-year course, a shorter trastuzumab course was associated with 33% lower odds of cardiac dysfunction (OR, 0.67; P<.001 and lower odds of congestive heart failure p=".003).</li">
- Small number of trials.
- No information on comorbidities or concurrent medications.